Executive Summary
The India Corporate Insolvency & NCLT stream reveals heightened distress in smaller listed companies, with Radhagobind Commercial Limited's ongoing CIRP featuring a 5th CoC meeting on March 21, 2026, and no resolution plans approved despite deadline extensions to March 17, 2026 midnight, signaling prolonged uncertainty. Remedium Lifecare Limited faces fresh NCLT admission on March 17, 2026, for a ₹7.47 Cr operational debt default (principal ₹6.19 Cr + interest ₹1.28 Cr at 18% p.a. from Nov 7, 2023), imposing a Section 14 moratorium. In contrast, Delhivery Limited secured positive NCLT approval on March 20, 2026, for merging loss-making subsidiaries (SLPL negative reserves ₹-12 Cr) into its robust ₹11,843 Cr equity base as of Dec 31, 2024, aiming for operational streamlining. Adani Power and Larsen & Toubro report neutral investor/media events on March 24 and March 21, 2026, respectively, with no UPSI or financial disclosures. No explicit YoY/QoQ trends across filings, but insolvency cases dominate (3/6 filings, 100% negative sentiment), underscoring portfolio risks in commercial, healthcare, and logistics sectors versus stability in power/infra giants. Market implications include potential delisting/wipeout for insolvents and efficiency gains for Delhivery.
Tracking the trend? Catch up on the prior India NCLT Insolvency Resolution Filings digest from March 20, 2026.
Investment Signals(11)
- Delhivery Limited↓(BULLISH)▲
NCLT New Delhi approved subsidiary merger effective Apr 1, 2025, streamlining operations and reducing compliances with parent equity ₹11,843 Cr (reserves ₹9,546 Cr) absorbing SLPL's -₹12 Cr reserves
- Radhagobind Commercial (Filing 1)(BEARISH)▲
CIRP ongoing post NCLT orders (Oct 30, 2025 IRP, Jan 27, 2026 RP), 5th CoC scheduled Feb 5, 2026, to review plans due Mar 17, 2026, but no outcomes disclosed
- Remedium Lifecare Limited(BEARISH)▲
NCLT Mumbai admitted CIRP Mar 17, 2026, on ₹7.47 Cr default (₹6.19 Cr principal from ₹18.36 Cr invoiced minus ₹12.17 Cr payments), full claim admission by debtor
- Radhagobind Commercial (Filing 6)(BEARISH)▲
5th CoC meeting held Mar 21, 2026 (4-5:48 PM), discussed late plans (post 5 PM to Mar 17 midnight), CIRP costs, interim finance needs, no approvals
- Delhivery Limited↓(BULLISH)▲
Wholly-owned subsidiary merger dispensed shareholder meetings via consents, board approvals 2023-2024, positive sentiment on resource optimization vs subsidiary losses
- Adani Power Limited↓(NEUTRAL-BULLISH)▲
Investor/analyst meeting at Morgan Stanley seminar Mar 24, 2026 (2-3 PM), routine Reg 30 disclosure indicating stable engagement
- Larsen & Toubro Limited↓(NEUTRAL-BULLISH)▲
Media interaction Mar 21, 2026 (6 PM Mumbai) on Middle East project continuity/safety, no UPSI, confirms operational resilience
- Remedium Lifecare Limited(BEARISH)▲
Moratorium under Section 14 halts recoveries/suits, IRP proposed Rajesh Jhunjhunwala, default authenticated via NeSL Form D from Nov 7, 2023
- Delhivery Limited↓(BULLISH)▲
Provisional BS Dec 31, 2024 shows strong equity positioning for merger absorption, contrasts sharply with SLPL/SSCSPL weaknesses
- Radhagobind Commercial↓(BEARISH)▲
Repeated CoC focus on CIRP costs/support services signals escalating expenses without resolution progress
- Adani Power & L&T(BULLISH)▲
Large-cap stability amid small-cap insolvencies, no financial distress indicators in neutral disclosures
Risk Flags(8)
- Radhagobind Commercial/Insolvency↓[HIGH RISK]▼
Prolonged CIRP (IRP Oct 2025, RP Jan 2026), 5th CoC Mar 21, 2026, highlights unresolved plans/CIRP costs/interim finance needs
- Remedium Lifecare/Debt Default[HIGH RISK]▼
₹7.47 Cr operational debt admitted in full (18% interest), moratorium from Mar 17, 2026, potential asset freeze/delisting
- Radhagobind Commercial/CIRP Costs↓[MEDIUM-HIGH RISK]▼
CoC discussions on costs to date and additional evaluation services indicate rising insolvency expenses eroding value
- Delhivery Limited/Merger Integration↓[MEDIUM RISK]▼
Absorbing SLPL -₹12 Cr reserves into ₹11,843 Cr equity, execution risks post ROC filing despite NCLT approval
- Remedium Lifecare/NCLT Admission[HIGH RISK]▼
Default from Nov 2023 (post partial payments ₹12.17 Cr), debtor withdrew objections, signals weak liquidity
- Radhagobind Commercial/Resolution Delay↓[HIGH RISK]▼
Plans accepted post-deadline to Mar 17 midnight, no quantified approvals post Feb 5 schedule shift to Mar 21
- General IBC/NCLT[PORTFOLIO RISK]▼
3/6 filings (50%) negative sentiment on CIRP admissions/meetings, small caps (BSE 030070, CSE 539673) vulnerable to wipeout
- Larsen & Toubro/Geopolitical↓[MEDIUM RISK]▼
Middle East media update amid regional tensions, asset/personnel safety queries highlight execution risks
Opportunities(8)
- Delhivery Limited/Merger Synergies↓(OPPORTUNITY)◆
NCLT-approved amalgamation streamlines logistics ops, optimizes resources post Apr 1, 2025, strong parent BS supports turnaround
- Radhagobind Commercial/Resolution Plans↓(OPPORTUNITY)◆
Late plans evaluated in 5th CoC Mar 21, 2026, potential for value-accretive bids from financial creditors
- Remedium Lifecare/IRPCoC Formation(OPPORTUNITY)◆
Fresh CIRP Mar 17, 2026, watch for resolution applicants in healthcare, undervalued assets post moratorium
- Adani Power/Investor Conference↓(OPPORTUNITY)◆
Morgan Stanley seminar Mar 24, 2026, platform for power sector updates, potential positive catalysts
- Larsen & Toubro/Middle East Continuity↓(OPPORTUNITY)◆
Media session Mar 21, 2026, reassures project execution/safety, alpha in infra stability amid geopolitics
- Delhivery Limited/Cost Optimization↓(OPPORTUNITY)◆
Merger reduces compliances for wholly-owned subs, equity strength (₹9,546 Cr reserves) vs losses positions for margin gains
- Radhagobind Commercial/Interim Finance↓(OPPORTUNITY)◆
CoC discussing financial creditor support, opportunity for distressed debt plays
- Remedium Lifecare/Claim Adjudication(OPPORTUNITY)◆
Full debt admission ₹7.47 Cr, potential for quick CoC formation and aggressive resolution in pharma
Sector Themes(5)
- Insolvency Dominance in Small Caps[BEARISH SECTOR RISK]◆
3/6 filings (Radhagobind x2, Remedium) on CIRP/NCLT, 100% negative sentiment, avg debt exposure ₹7.47 Cr+, risks delisting vs large-cap stability
- Logistics Restructuring Positive(BULLISH SUB-THEME)◆
Delhivery merger absorbs -₹12 Cr sub losses into ₹11,843 Cr equity, contrasts healthcare/commercial distress, signals consolidation trend
- Prolonged CIRP Timelines(BEARISH THEME)◆
Radhagobind CoC from Feb 5 to Mar 21, 2026, with late plan deadlines, average process >4 months post-IRP, eroding creditor recoveries
- Neutral Large-Cap Events(STABILITY THEME)◆
Adani Power/L&T disclosures (Mar 24/21, 2026) materiality 3/10, no metrics but affirm continuity amid small-cap turmoil
- Debt Default Patterns[RISK THEME]◆
Remedium 18% p.a. interest on ₹6.19 Cr principal (post ₹12.17 Cr payments), NeSL-authenticated, highlights operational creditor leverage in IBC
Watch List(7)
Monitor post-Mar 21, 2026 outcomes on plan approvals/CIRP costs, potential resolution timeline shift [Ongoing]
- Remedium Lifecare/IRPCoC Formation👁
Track Interim RP Rajesh Jhunjhunwala appointment confirmation, first CoC post-Mar 17, 2026 NCLT order [Next 30 days]
Watch merger effectiveness upon ROC submission post-Mar 20, 2026 NCLT approval, integration updates [Imminent]
Mar 24, 2026 (2-3 PM) investor meeting, potential power sector guidance despite no UPSI [Mar 24, 2026]
Mar 21, 2026 (6 PM) media interaction outcomes on project safety, query responses [Mar 21, 2026]
Post-Mar 17 midnight submissions evaluation, interim finance approvals from Mar 21 CoC [Next Week]
- Remedium Lifecare/Moratorium Impacts👁
Section 14 effects on operations/suits, creditor claims post-₹7.47 Cr admission [Ongoing]
Filing Analyses(6)
21-03-2026
Radhagobind Commercial Limited (CIN: L51909WB1981PLC033680) is under Corporate Insolvency Resolution Process (CIRP), with Adv. Najeeb T P appointed as Interim Resolution Professional (NCLT order dated 30.10.2025) and Resolution Professional (NCLT order dated 27.01.2026). The 5th Committee of Creditors (COC) meeting is scheduled for February 5, 2026, at 4:00 PM in Kannur, Kerala (also via VC), to review CIRP progress, resolution plans received until midnight March 17, 2026, CIRP costs to date, and related matters. No financial performance metrics or resolution outcomes are disclosed.
- ·NCLT Kolkata Bench orders: CP (IB)/71/KB/2025 dated 30.10.2025 (IRP appointment); IA (I.B.C)/90(KB)2026 dated 27.01.2026 (RP appointment)
- ·Scrip Codes: BSE 030070, CSE 539673
- ·Meeting venue: Baithussalam, Balankinar, Kattampally Road, Near Indus Motors Maruthi Service Centre, Kannur 670011, Kerala
- ·Contact: najetpip@gmail.com, radhagobindcirp2025@gmail.com, Mob: +91-9846603236
21-03-2026
The NCLT New Delhi approved the Scheme of Amalgamation on March 20, 2026, merging wholly-owned subsidiaries Spoton Logistics Private Limited (SLPL) and Spoton Supply Chain Solutions Private Limited (SSCSPL) into Delhivery Limited, effective from the Appointed Date of April 1, 2025, upon filing with ROC. The merger aims to streamline operations, reduce compliances, and optimize resources, with Delhivery's provisional balance sheet as of Dec 31, 2024 showing total equity & liabilities of ₹11,843 Cr including reserves of ₹9,546 Cr. However, SLPL reports negative reserves of ₹-12 Cr on its provisional balance sheet.
- ·SLPL CIN: U63090DL2011PTC409002; SSCSPL CIN: U74200DL2008PTC404706; Delhivery CIN: L74200DL2008PTC404706 (noted discrepancy in CIN for Delhivery).
- ·Board approvals: SLPL on Nov 2, 2023; SSCSPL on Jan 31, 2024; Delhivery on Feb 2, 2024.
- ·First Motion order dated Aug 29, 2024; dispensed with shareholder/creditor meetings as wholly-owned subsidiaries with consents.
- ·Scheme effective upon filing certified NCLT order with ROC.
21-03-2026
Adani Power Limited has notified BSE and NSE under Regulation 30 of SEBI LODR about a virtual group meeting with investors and analysts at the Morgan Stanley India Industrials & Energy Seminar (Equity Conference) on March 24, 2026, from 2:00 p.m. to 3:00 p.m. local time. The intimation was filed on March 21, 2026. No financial or operational details were disclosed in this routine disclosure.
- ·Scrip Code: 533096 (BSE), ADANIPOWER (NSE)
- ·CIN: L40100GJ1996PLC030533
- ·Registered Office: “Adani Corporate House”, Shantigram, Near Vaishno Devi Circle, S. G. Highway, Khodiyar, Ahmedabad-382421, Gujarat, India
21-03-2026
Larsen & Toubro Limited is hosting a media interaction on March 21, 2026, at 6:00 p.m. in Mumbai to provide high-level updates on project execution progress in the Middle East region, including maintenance of operational continuity amid the prevailing environment, and measures for employee safety, security, and welfare. The session will address media queries on the safety of assets, projects, and personnel deployed in Middle East geographies. The company confirms no unpublished price sensitive information (UPSI) will be shared.
- ·Media interaction protocols activated in response to current regional situation in Middle East
- ·Contact details: Tel: +91 22 6752 5656, Fax: +91 22 6752 5858, Email: igrc@larsentoubro.com
- ·Stock codes: BSE 500510, NSE LT
21-03-2026
The National Company Law Tribunal (NCLT) Mumbai Bench-VI admitted C.P.(IB)/579/MB/2025 filed by Boston Ivy Healthcare Solution Private Limited (Operational Creditor) against Remedium Lifecare Limited (Corporate Debtor) under Section 9 of the IBC on 17.03.2026, initiating Corporate Insolvency Resolution Process (CIRP) due to an admitted operational debt default of ₹7.47 Cr as of 07.11.2023. The debt comprises principal of ₹6.19 Cr (out of total invoiced ₹18.36 Cr after partial payments of ₹12.17 Cr) and interest of ₹1.28 Cr at 18% p.a.; the Corporate Debtor withdrew all objections and admitted the claim in full. A moratorium under Section 14 is declared, prohibiting suits, asset transfers, and recoveries, with Mr. Rajesh Jhunjhunwala proposed as Interim Resolution Professional.
- ·Date of default: 07.11.2023 (authenticated via NeSL Form D)
- ·Application filed: 07.05.2025
- ·Demand notice issued: 13.03.2025 under Section 8 IBC
- ·Invoices dated: 24.07.2023, 03.08.2023, 09.08.2023, and MH/23-24/29596 (implied 11.11.2023)
- ·Zero (0) day credit period in invoices; interest from next day of default
- ·IRP validity: AFA up to 31.12.2026; no disciplinary proceedings
21-03-2026
The 5th meeting of the Committee of Creditors (CoC) for Radhagobind Commercial Limited was held on March 21, 2026, chaired by Resolution Professional Adv. Najeeb T P, discussing progress in the Corporate Insolvency Resolution Process (CIRP), including acceptance of resolution plans received even after 5:00 pm up to midnight on March 17, 2026. Matters covered CIRP costs to date, needs for additional support services for plan evaluation, and interim finance from financial creditors. No specific financial approvals or resolutions were quantified, highlighting ongoing insolvency challenges without resolution.
- ·NCLT Kolkata Bench orders: CP (IB)/71/KB/2025 dated 30.10.2025 (IRP appointment) and IA (I.B.C)/90(KB)2026 dated 27-01-2026 (RP appointment)
- ·CoC meeting held from 4:00 pm to 5:48 pm on 21-03-2026
- ·Scrip Codes: BSE 030070, CSE 539673
- ·CIN: L51909WB1981PLC033680
Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 6 filings
🇮🇳 More from India
View all →March 26, 2026
India Pre-Market Regulatory Roundup — March 26, 2026
India Pre-Market Regulatory Roundup
March 26, 2026
India Quarterly Results BSE NSE Announcements — March 26, 2026
India Quarterly Results BSE NSE Announcements
March 26, 2026
India Upcoming Corporate Actions BSE NSE — March 26, 2026
India Upcoming Corporate Actions BSE NSE
March 26, 2026
India MCA Insolvency Liquidation Filings — March 26, 2026
India MCA Insolvency Liquidation Filings